The global injectable drug for type diabetes market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The increase in the prevalence of type 2 diabetes disease has created a demand for the development of new drugs for its treatment which in turn drives the global injectable drug for type diabetes market growth. According to the NCBI (National Center for Biotechnology Information), the number of people diagnosed with diabetes is expected to reach more than 600 million. Additionally, type 2 diabetes mellitus accounts for about 90% of all diabetes cases and as a result of this increase in patients with diabetes, the market for injectable drugs for type diabetes is expected to grow significantly.
Furthermore, with the growing popularity of online pharmacies the drug supply chain in the drug delivery sector is expected to improve significantly, these developments increased the global injectable drug for diabetes market is expected to rise in the forecast period. Additionally, leading pharmaceutical companies are focusing on the development of drugs for type 2 diabetes treatment. Therefore, the market growth is driven by the strong focus of the pharmaceutical companies and research organizations on the R&D of drugs for injectable type 2 diabetesdrugs creating a strong medicine for effective treatment.
Key players in the market include GlaxoSmithKline Plc., Merck & Co., Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., and Pfizer Inc. among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2019, Novo Nordisk A/S announced the Rybelsus oral tablets for adult patients with type 2 diabetes. With this approval, Rybelsus has become the first glucagon-like peptide (GLP-1) of protein receptor protein treatment that is approved for use in the US, which does not require injection for diabetes patients, that new reorganization produced by the injectable drug for type diabetes market, which increased the demand for this market.
(Get 15% Discount on Buying this Report)
Get Sample Copy of global injectable drug for type diabetes market at:
https://orionmarketreports.com/request-sample/?id=95335&submit=Request+Sample%0D%0A
Market Coverage
The market number available for – 2021-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
By Drug Type
By Application
By Distribution Channel
Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World
Competitive Landscape-
AbbVie Inc., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly & Co., Takeda Pharmaceutical Co. Ltd., among others.
Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?
A full report of global injectable drug for type diabetes market is available at:
https://orionmarketreports.com/global-injectable-drugs-for-type-diabetes-market/95335/
Global Injectable Drug For Type Diabetes Market Report by Segment
By Drug Type
Insulin
Exenatide
Liraglutide
Pramlintide
By Application
Glycemic Control
Cardiovascular Safety
Hypoglycemic Avoidance
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
